INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Other EventsItem 8.01 – Other Events
On September 26, 2017, the Company issued a press release announcing the availability of the full label for its nasal drug FlutiCare™ (NDC: 57483-005-02) for allergy symptom relief on the U.S. Food and Drug Administration’s public drug disclosure database, DailyMed. DailyMed is the on-line database that all new drugs are described on that provides information to the public on its ingredients and usage. The DailyMed description is available through the site below:
The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 — Financial Statements and Exhibits
Press release issued September 27, 2017.
INNOVUS PHARMACEUTICALS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint Exhibit 99.1 Innovus Pharma Announces the Availability of the Full Label for its Nasal Drug FlutiCare™ for Allergy Symptom Relief on DailyMed FlutiCare™ is on Track for a November 2017 Launch in the U.S. San Diego,…To view the full exhibit click
About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.